Product Code: PM3553
The global aptamers market size is expected to reach USD 16.33 billion by 2032, according to a new study by Polaris Market Research. The report "Aptamers Market Share, Size, Trends, Industry Analysis Report, By Type (Nucleic Acid, and Peptide); By Application (Diagnostics, Therapeutics, Research & Developments, and Others); By Region, And Segment Forecasts, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Versatility of aptamers and their potential applications in various industries such as healthcare, biotechnology, and diagnostics have attracted the attention of many companies. Moreover, the availability of customized aptamers for specific targets has expanded the applications of aptamers beyond their traditional use in research and diagnostics. This has led to the development of new aptamer-based products, including therapeutics and biosensors, which are expected to further drive the growth of the aptamers market.
The SELEX technology has been used to develop aptamers that can bind to specific biomarkers related to SARS-CoV-2 and COVID-19, allowing for the development of diagnostic kits and assays. These aptamer-based diagnostic tools can provide high sensitivity and specificity in detecting the virus and related biomarkers, which can aid in disease diagnosis and monitoring. As a result, the introduction of such diagnostic kits and assays in the market is expected to drive the growth of the market.
In December 2021, Achiko AG's Aptamex, a COVID-19 diagnostic kit, received approval from the health ministry of Indonesia. Aptamex is a 2nd generation kit developed using DNA aptamer technology, which is cost-effective, chemically synthesized, diagnostic kit in the pharmaceuticals.
Market growth is further supported by various regulatory agencies such as the U.S. FDA, Health Canada, EMA, COFEPRIS, MHRA, & CDSCO, which have taken initiatives to support the research and development in this field. For example, in March 2020, the U.S. FDA granted Fast Track designation to IVERIC Bio's Zimura for the treatment of patients with geographic atrophy (GA) secondary to AMD. It is a pegylated RNA aptamer, which is synthesized & administered by the intra-vitreal injection. It works by the inhibition of factor C5, considered responsible for onset of AMD.
Aptamers Market Report Highlights
Nucleic acid segment dominated the market, owing to rapid development in the diagnostics, therapeutics, and advancements in the biomarker discovery
R&D segment accounted for the larger market share, as there is a strong interest in aptamer manufacturing companies, and favorable government initiatives
Diagnostic segment recorded fastest growth rate, owing to rising need for aptamer based diagnostic kits for the early disease diagnosis
North America garnered the largest share, owing to the presence of companies engaged in the development of aptamers, and strong industry academia collaboration for scientific breakthroughs
Asia Pacific is projected to register a higher growth rate, owing to the presence of large patient pool, huge untapped population, and favorable government policies for research.
The global players include: Base Pair Biotechnologies, SomaLogic, Aptadel Therapeutics, Aptamer Group, Noxxon Pharma, Aptagen, TriLink Biotechnologies, Altermune, Vivonics, and AM Biotechnologies.
Polaris Market Research has segmented the aptamers market report based on type, application, and region:
Aptamers, Type Outlook (Revenue - USD Billion, 2019 - 2032)
- Nucleic Acid Aptamer
- Peptide Aptamer
Aptamers, Application Outlook (Revenue - USD Billion, 2019 - 2032)
- Diagnostics
- Therapeutics
- Research and Development
- Others
Aptamers, Regional Outlook (Revenue - USD Billion, 2019 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Latin America
- Argentina
- Brazil
- Mexico
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
3. Research Methodology
- 3.1. Overview
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Aptamers Market Insights
- 4.1. Aptamers Market - Industry Snapshot
- 4.2. Aptamers Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising number of the advantages of aptamers over antibodies
- 4.2.1.2.Rising prevalence of chronic and rare disease
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Growth in the venture capital funding for research on aptamers
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTLE Analysis
- 4.5. Aptamers Industry trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Aptamers Market, by Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Aptamers, by Type, 2019-2032 (USD Billion)
- 5.3. Nucleic Acid Aptamer
- 5.3.1. Global Aptamers Market, by Nucleic Acid Aptamer, by Region, 2019-2032 (USD Billion)
- 5.4. Peptide Aptamer
- 5.4.1. Global Aptamers Market, by Peptide Aptamer, by Region, 2019-2032 (USD Billion)
6. Global Aptamers Market, by Application
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Aptamers Market, by Application, 2019-2032 (USD Billion)
- 6.3. Diagnostics
- 6.3.1. Global Aptamers Market, by Diagnostics, by Region, 2019-2032 (USD Billion)
- 6.4. Therapeutics
- 6.4.1. Global Aptamers Market, by Therapeutics, by Region, 2019-2032 (USD Billion)
- 6.5. Research and Development
- 6.5.1. Global Aptamers Market, by Research and Development, by Region, 2019-2032 (USD Billion)
- 6.6. Others
- 6.6.1. Global Aptamers Market, by Others, by Region, 2019-2032 (USD Billion)
7. Global Aptamers Market, by Geography
- 7.1. Key findings
- 7.2. Introduction
- 7.2.1. Aptamers Market Assessment, By Geography, 2019-2032 (USD Billion)
- 7.3. Aptamers Market - North America
- 7.3.1. North America: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.3.2. North America: Aptamers Market, by Type, 2019-2032 (USD Billion)
- 7.3.3. Aptamers Market - U.S.
- 7.3.3.1. U.S.: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.3.3.2. U.S.: Aptamers Market, by Type, 2019-2032 (USD Billion)
- 7.3.4. Aptamers Market - Canada
- 7.3.4.1. Canada: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.3.4.2. Canada: Aptamers Market, by Type, 2019-2032 (USD Billion)
- 7.4. Aptamers Market - Europe
- 7.4.1. Europe: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.4.2. Europe: Aptamers Market, by Type, 2019-2032 (USD Billion)
- 7.4.3. Aptamers Market - UK
- 7.4.3.1. UK: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.4.3.2. UK: Aptamers Market, by Type, 2019-2032 (USD Billion)
- 7.4.4. Aptamers Market - France
- 7.4.4.1. France: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.4.4.2. France: Aptamers Market, by Type, 2019-2032 (USD Billion)
- 7.4.5. Aptamers Market - Germany
- 7.4.5.1. Germany: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.4.5.2. Germany: Aptamers Market, by Type, 2019-2032 (USD Billion)
- 7.4.6. Aptamers Market - Italy
- 7.4.6.1. Italy: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.4.6.2. Italy: Aptamers Market, by Type, 2019-2032 (USD Billion)
- 7.4.7. Aptamers Market - Spain
- 7.4.7.1. Spain: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.4.7.2. Spain: Aptamers Market, by Type, 2019-2032 (USD Billion)
- 7.4.8. Aptamers Market - Netherlands
- 7.4.8.1. Netherlands: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.4.8.2. Netherlands: Aptamers Market, by Type, 2019-2032 (USD Billion)
- 7.4.9. Aptamers Market - Russia
- 7.4.9.1. Russia: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.4.9.2. Russia: Aptamers Market, by Type, 2019-2032 (USD Billion)
- 7.5. Aptamers Market - Asia Pacific
- 7.5.1. Asia Pacific: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.5.2. Asia Pacific: Aptamers Market, by Type, 2019-2032 (USD Billion)
- 7.5.3. Aptamers Market - China
- 7.5.3.1. China: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.5.3.2. China: Aptamers Market, by Type, 2019-2032 (USD Billion)
- 7.5.4. Aptamers Market - India
- 7.5.4.1. India: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.5.4.2. India: Aptamers Market, by Type, 2019-2032 (USD Billion)
- 7.5.5. Aptamers Market - Malaysia
- 7.5.5.1. Malaysia: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.5.5.2. Malaysia: Aptamers Market, by Type, 2019-2032 (USD Billion)
- 7.5.6. Aptamers Market - Japan
- 7.5.6.1. Japan: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.5.6.2. Japan: Aptamers Market, by Type, 2019-2032 (USD Billion)
- 7.5.7. Aptamers Market - Indonesia
- 7.5.7.1. Indonesia: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.5.7.2. Indonesia: Aptamers Market, by Type, 2019-2032 (USD Billion)
- 7.5.8. Aptamers Market - South Korea
- 7.5.8.1. South Korea: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.5.8.2. South Korea: Aptamers Market, by Type, 2019-2032 (USD Billion)
- 7.6. Aptamers Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.6.2. Middle East & Africa: Aptamers Market, by Type, 2019-2032 (USD Billion)
- 7.6.3. Aptamers Market - Saudi Arabia
- 7.6.3.1. Saudi Arabia: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.6.3.2. Saudi Arabia: Aptamers Market, by Type, 2019-2032 (USD Billion)
- 7.6.4. Aptamers Market - UAE
- 7.6.4.1. UAE: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.6.4.2. UAE: Aptamers Market, by Type, 2019-2032 (USD Billion)
- 7.6.5. Aptamers Market - Israel
- 7.6.5.1. Israel: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.6.5.2. Israel: Aptamers Market, by Type, 2019-2032 (USD Billion)
- 7.6.6. Aptamers Market - South Africa
- 7.6.6.1. South Africa: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.6.6.2. South Africa: Aptamers Market, by Type, 2019-2032 (USD Billion)
- 7.7. Aptamers Market - Latin America
- 7.7.1. Latin America: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.7.2. Latin America: Aptamers Market, by Type, 2019-2032 (USD Billion)
- 7.7.3. Aptamers Market - Mexico
- 7.7.3.1. Mexico: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.7.3.2. Mexico: Aptamers Market, by Type, 2019-2032 (USD Billion)
- 7.7.4. Aptamers Market - Brazil
- 7.7.4.1. Brazil: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.7.4.2. Brazil: Aptamers Market, by Type, 2019-2032 (USD Billion)
- 7.7.5. Aptamers Market - Argentina
- 7.7.5.1. Argentina: Aptamers Market, by Application, 2019-2032 (USD Billion)
- 7.7.5.2. Argentina: Aptamers Market, by Type, 2019-2032 (USD Billion)
8. Competitive Landscape
- 8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
- 8.2. Partnerships/Collaborations/Agreements/Exhibitions
9. Company Profiles
- 9.1. Base Pair Biotechnologies
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
- 9.2. SomaLogic
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
- 9.3. Aptadel Therapeutics
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
- 9.4. Aptamer Group
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
- 9.5. Noxxon Pharma
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
- 9.6. Aptagen
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
- 9.7. TriLink Biotechnologies
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
- 9.8. Altermune
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
- 9.9. Vivonics
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
- 9.10. AM Biotechnologies
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development